MedPath

Evaluation of the OSNA method for the detection of lymph node metastases in women with endometrial cancer - A feasibility study

Recruiting
Conditions
C54.1
Endometrium
Registration Number
DRKS00021520
Lead Sponsor
Sysmex Europe GmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
300
Inclusion Criteria

• After reviewing the patient information sheet, the patient's written consent must be given
• Patients with endometrial cancer who are undergoing SLNB

Exclusion Criteria

• Patients who are affected by other metastatic cancer
• Patients judged to be incapable of participating in the study by the investigator
• Patient choice

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
• Diagnostic sensitivity<br>• Diagnostic specificity<br>• Positive predictive value<br>• Negative predictive value<br>• Likelihood ratio<br>• Expected values in normal and affected populations<br><br>The endpoints are collected at the end of recruitment.
Secondary Outcome Measures
NameTimeMethod
• Concordance between OSNA and ultra-staging
© Copyright 2025. All Rights Reserved by MedPath